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a  b  s  t  r  a  c  t
Factor  H  (FH)  is  the  major  plasma  regulator  of  the  central  complement  protein  C3b in  the  alternative
pathway  of complement  activation.  The  elucidation  of the  FH interactions  with  ﬁve  major  ligands  (below)
is complicated  by their  weak  M dissociation  constants  KD and  FH  multivalency.  We  present  the  ﬁrst
survey  of  all  the  KD values  for the  major  FH–ligand  interactions  and  critically  review  their  physiological
signiﬁcance.
(i)  FH  self-association  is  presently  well-established.  We  review  multiple  data  sets  that  show  that  5–14%
of  FH  is self-associated  in physiological  conditions.  FH  self-association  is  signiﬁcant  for  both  laboratory
investigations  and  physiological  function.
(ii) The FH–C3b  complex  shows  low  M afﬁnity,  meaning  that  the  complex  is not  fully  formed  in  plasma.  In
addition,  C3,  its  hydrolysed  form  C3u,  and  its  cleaved  forms  C3b and  C3d  show  multimerisation.  Current
data  favour  a  model  when  two  C3b  molecules  bind  independently  to one  FH  molecule,  as  opposed  to  a
1:1  stoichiometry  where  FH  wraps  itself  around  C3b.
(iii)  Heparin  is  often  used  as an analogue  of  the  polyanionic  host  cell  surface.  The  FH–heparin  complex  also
shows  a  low  M afﬁnity,  again  meaning  that  complexes  are  not  fully  formed  in vivo.  The  oligomeric
FH–heparin  complexes  clarify  a two-site  interaction  model  of  FH  with  host-cell  surfaces.
(iv)  Reinvestigation  of  the FH  and  C-reactive  protein  (CRP)  interaction  revealed  that  this  can  only  occur  in
plasma  when  CRP  levels  are  elevated  during  acute-phase  conditions.  Given  that  CRP  binds  more  weakly
to  the  His402  allotype  of FH  than  the  Tyr402  allotype,  this  suggested  a link  with  age-related  macular
degeneration  (AMD).
(v)  FH  activity  is  inhibited  by  zinc,  which  causes  FH  to  aggregate  strongly.  High  levels  of  bioavailable  zinc
occur  in  sub-retinal  pigment  epithelial  deposits  which  lead  to AMD.  Excess  zinc  binds  weakly  to a
central  region  of  FH,  explaining  how  zinc  inhibits  FH regulation  of  C3b.© 2011 Elsevier GmbH. All rights reserved.
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omplement Factor H interactions in plasma
In plasma, the serum proteins total about 70 mg/ml. The
ost overwhelmingly abundant protein (60% of the total) is
uman serum albumin (molecular weight 65,000 Da) that circu-
ates in plasma at reference levels between 30 and 50 mg/ml
450–750 M)  (Putnam 1975; Lu et al. 2008). This is followed by the
mmunoglobulins (10–15 mg/ml; IgG molecular weight 150 kDa;
oncentration 67–100 M).  Five plasma proteins present in mod-
rate amounts include ﬁbrinogen (2–5 mg/ml; 169 kDa; 9 M),
1-antitrypsin (2–4 mg/ml; 40 kDa), haptoglobulin (1–2.2 mg/ml;
00 kDa), 2-macroglobulin (1.5–4.2 mg/ml; 725 kDa), and trans-
errin (2–4 mg/ml; 77 kDa) (Putnam 1975). The 30–40 complement
roteins (Walport 2001; Janeway et al. 2005) make up 2.6 mg/ml
n total, and many are typically present at concentrations in the
.3–7 M range (Law and Reid 1995). The plasma concentrations
f acute phase proteins increase or decrease in response to inﬂam-
ation. Under acute phase conditions, some complement protein
oncentrations and related ones, including C3, C4 and especially C-
eactive protein (CRP), go much higher. Many of the complement
roteins are therefore abundant in comparison to other serum pro-
eins such as the coagulation cascade proteases. The six coagulation
actors V, VII, VIII, IX, X and XI, together with von Willebrand factor,
irculate at 0.1–10 g/ml which corresponds to nanomolar levels of
rotein (0.3–135 nM). Modern proteomics methods complete the
icture by showing that there are as many as 1000–2000 other
lasma proteins with concentrations reaching as low as picomolar
evels (5 ng/ml) (Anderson 2010).
Complement is a major defence and clearance system in blood,
his being activated by pathogens such as bacteria by one of three
athways, the classical, lectin or alternative pathways. All three
athways lead to the activation of C3, the central complement
omponent, to C3b (Fig. 1). C3b formation ultimately leads to the
ormation of a membrane attack complex that lyses bacteria and
he clearance of C3b-opsonized cells by phagocytosis. The C3b level
equires regulation. Too much C3b activation will lead to host dam-
ge, while too little C3b activation means that the host becomes
usceptible to infection. This is often referred to as the “double-
dged sword” nature of complement activation and regulation
Zipfel and Skerka 2009; Ricklin et al. 2010). In the context of the
lasma proteins, both C3 and the major C3b regulator Factor H (FH:
ig. 1) are comparatively abundant. C3 is reported in typical con-
entration ranges of 1.0 mg/ml, 1.3 mg/ml  or 1.6 mg/ml  (5–8.5 M)
Putnam 1975; Law and Reid1995; Nilsson and Ekdahl 1998), while
H is reported to be at 0.116–0.562 mg/ml  (0.8–3.6 M)  (Rodriguez
e Cordoba and Goicoechea de Jorge 2008) and 0.235–0.81 mg/ml
2–5 M)  (Saunders et al. 2006). C3 exhibits a modest acute-phase
esponse with a 50% increase in plasma concentration (Gabay and
ushner 2001). The comparative abundance of C3 is most likely
o result from an essential requirement to maintain enough C3 in
lasma in order to combat infections, while the abundance of FH is
ttributable to the need to adequately regulate C3b for host protec-
ion. This C3b regulation is achieved by the two-fold role of FH in
i) blocking the binding of complement Factor B to C3b, and com-
eting with and displacing the Bb fragment that binds to C3b to
orm the C3b convertase enzyme that generates even more C3b,
nd (ii) acting as a cofactor of the protease Factor I for the pro-
eolytic cleavage of C3b to form the inactive fragments C3d and
3c. FH functions both in solution in plasma and also by binding
o host cell surfaces through interactions with oligosaccharides . . . .  . . .  . . . . .  .  .  . .  .  . . . . .  . .  . . . . . . .  .  . . . .  . . .  .  . . .  . . .  .  .  . . . . .  .  .  .  .  .  . . . . . . . . . .  .  . .  .  . 295
bearing clusters of negative charges or motifs of high negative
charge density.
The strength of the FH–C3b interaction and others is key to
understanding this crucial stage of complement activation. This
is monitored by the dissociation constant KD. The KD value for an
interaction is also often comparable to the macromolecular con-
centrations. Given that C3 and FH are found at 2–7 M levels in
plasma, it is unsurprising that the KD values for their ligand inter-
actions are also in similar M ranges. In this review, the FH and
ligand concentrations are accordingly reported in both mg/ml and
M units. For a 1:1 FH–ligand equilibrium, the KD value is given
by [FH][ligand]/[complex], and KD corresponds to the FH concen-
tration at which the complex is 50% dissociated. It is noteworthy
that the absence of strong FH afﬁnities with KD values in nM ranges
means that FH participates only in partially formed complexes with
C3b and heparin. The M afﬁnities for FH–ligand complexes mean
that these moderately strong interactions can be missed in bio-
chemical assays. Examples of this will be noted below in relation
to FH–CRP and FH–zinc interaction studies.
In addition to the weak M KD values, an understanding of
FH–ligand interactions is also complicated for two  additional rea-
sons. Firstly, FH undergoes 5–14% self-association, both in the
test-tube and in physiological milieu (Nan et al. 2008a). This is
disregarded by some investigators; their resulting analyses of FH
interactions do not take advantage of this knowledge and the
conclusions can be misleading. Examples will be noted below in
relation to studies of FH itself, and in the FH–C3b and FH–heparin
interaction studies. Secondly, FH undergoes multivalent interac-
tions with its C3b, C3d, heparin and CRP ligands. Multivalency
means that the conventional analyses of protein complexes in
terms of simple 1:1 interactions may  not be adequate in quantita-
tive studies. In particular for FH, the study of small recombinant FH
fragments–ligand complexes requires comparisons with the inter-
action based on full-length FH as a control. An example discussed
later involves the interaction between C3d and FH.
Many FH–ligand interactions are formed through opposing ionic
interactions between FH and its ligands. Given the weak M KD val-
ues, the interactions become stronger and more easily observed if
buffer compositions with reduced salt levels such as 50 mM NaCl
are used in place of the plasma level of 137 mM NaCl and 11 mM
phosphate. Higher salt levels than those in plasma will inhibit inter-
actions that have an electrostatic component. Comparisons with
low (50 mM NaCl) and high (250 mM NaCl) salt levels are use-
ful to unravel the signiﬁcance of electrostatic forces for a given
FH–ligand interaction. However the use of 50 mM NaCl buffer can
promote non-physiological interactions between FH and its lig-
ands. An example of this involves C3d self-association (Table 1).
Low salt was used in many of the ﬁrst studies of the FH interactions
with its ligands, and the KD values are reduced (stronger binding)
for this reason (Table 1). An example is discussed in more detail for
the FH–CRP interaction.
The use of 137 mM NaCl is preferred for FH–ligand studies,
while 150 mM NaCl is also reasonable. Blood pH is regulated to
stay within the narrow range of 7.35–7.45, and this pH is princi-
pally determined by the bicarbonate equilibrium and the surface
histidine residues of haemoglobin. In that context, blood contains
phosphate (a ratio of 1:4 NaH2PO4 and Na2HPO4 yields a pH of
7.4). Dulbecco’s Phosphate Buffered Saline (PBS) is a standard buffer
used to replicate plasma buffer, with a formulation of 137 mM NaCl,
2.7 mM KCl, 8.1 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4 (Dulbecco
S.J. Perkins et al. / Immunobiology 217 (2012) 281– 297 283
Fig. 1. Domain structure of Factor H and its ligands. (a) Schematic view of the 20 SCR domains of FH. The positions of two C3b binding sites (SCR-1/4 having decay accelerating
and  factor I activity), two heparin-binding sites on SCR-7 and SCR-20, two  C3d binding sites on SCR-19 and SCR-20, two  C-reactive protein binding sites at SCR-6/8 and SCR-
16/20,  and weak zinc binding sites at SCR-6/8 are shown schematically. The location of eight N-linked glycosylation sites is shown by symbols; a ninth site at SCR-4 is not
occupied. (b) Comparison of molecular views to the same scale of a solution structure for FH with structures for its C3b, C3d, heparin and CRP ligands. A folded-back domain
arrangement of a best-ﬁt FH structural model is shown with its longest length running from left to right (SCR-1 to SCR-20). The FH structure is from two recent studies
(Okemefuna et al. 2009a; Nan et al. 2010). The C3b-binding SCR-1/4 domains are shown in red, with C3b shown in cyan, and its CUB and TED domains shown in purple and
yellow. The heparin- and CRP-binding SCR-7 domain is shown in red, with the CRP pentamer shown edge-on in blue. The bent SCR central region of FH with the shorter and
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(lycosylated SCR domains are shown to the bottom right. The two  C3d proteins bou
tands for degree of polymerisation) is shown in green. The eight FH oligosaccharid
he  reader is referred to the web version of the article.)
nd Vogt 1954). PBS has many uses because it is isotonic and non-
oxic to cells. Its osmolarity and ion concentration matches that of
he human body. If required, such as in studies with CRP, 2 mM cal-
ium should be added to correspond to the 2.5 mM level of calcium
ound in plasma (Hurwitz 1996). Normal saline used in intravenous
rips contains 154 mM NaCl, which is slightly higher in osmolarity
han that found in blood. This higher NaCl level compensates for the
resence of 11 mM phosphate in PBS, i.e. the presence of other pro-
eins and chemicals in plasma. Twelve buffering agents have been
escribed that are good candidates for biological work (Good et al.
966). These include HEPES (pK  7.55) which is advantageous when
inc is present so long as 137 mM NaCl is also present (Table 1),
ecause phosphate is precipitated by zinc.
Here, we review FH in terms of FH, C3 and CRP self-association,
H multivalency, and a survey of all the known dissociation con-
tants KD for its FH–ligand interactions. These are discussed in
he context of FH and ligand concentrations and the experimen-
al buffers in use. Other recent reviews of FH interactions discuss
H in relation to age-related macular degeneration (AMD) (Perkins
t al. 2010a)  and the biophysical basis of the FH–CRP interaction
Perkins et al. 2010b).  The functional context of FH in diseasesSCR-19 and SCR-20 are shown in yellow, while heparin dp36 (18 disaccharides; dp
 shown in grey. (For interpretation of the references to color in this ﬁgure legend,
such as AMD  and atypical haemolytic uraemic syndrome (aHUS)
is reviewed elsewhere (Rodriguez de Cordoba and Goicoechea de
Jorge 2008; Holers 2008; Zipfel and Skerka 2009; Ricklin et al.
2010). For example, the Tyr402His polymorphism in FH enhances
the risk for AMD.
Interaction sites of Factor H by biophysical methods
In summary, FH is constructed from 20 short complement reg-
ulator (SCR) domains, each of length about 61 residues, joined by
linkers between 3 and 8 residues in size (Fig. 1). The SCR domains
constitute the most abundant domain type in the complement sys-
tem. They were originally termed as “short consensus repeat” (SCR)
and subsequently as “complement control protein” (CCP) domains.
The redeﬁnition of SCR as “short complement regulator” makes
better sense of this more commonly used acronym. FH has major
N-terminal and C-terminal binding sites for C3b at SCR-1/4 and
SCR-19/20 (Fig. 1a) (Schmidt et al. 2008). A third C3b binding site
speciﬁc for C3c has been proposed in the central part of FH (Sharma
and Pangburn 1996; Jokiranta et al. 2000; Schmidt et al. 2008).
There are also two heparin binding sites at SCR-7/8 and SCR-19/20
284 S.J. Perkins et al. / Immunobiology 217 (2012) 281– 297
Table  1
Survey of dissociation constants KD for the FH interactions with its ligands.
Interaction KD (M) Methoda Buffer (abbreviated) Reference
FH self-association
FH–FH 28 SE 10 mM HEPES with 137 mM NaCl and EDTA, pH 7.4 Nan et al. (2008a)
FH–FH >8 SPR 10 mM HEPES with 137 mM NaCl and EDTA, pH 7.4 Nan et al. (2010)
SCR-6/8–SCR-6/8 (His402) 40 SE PBS with 137 mM NaCl, pH 7.3 Fernando et al. (2007)
SCR-16/20–SCR-16/20 13–18 SE, SAXS PBS with 137 mM NaCl, pH 7.3 Okemefuna et al. (2008)
FH–C3  interactions
C3d–C3d 23 SE 10 mM HEPES, 50 mM NaCl, pH 7.4 Perkins et al. (2005, 2008)
C3d–C3d No complex SV PBS with 137 mM NaCl, pH 7.4 Li et al. (2008)
C3–C3;  C3u–C3u 38 SV PBS with 50 mM NaCl, pH 7.4 Li et al. (2010)
C3–C3;  C3u–C3u 38–53 SV PBS with 137 mM NaCl, pH 7.4 Li et al. (2010)
FH–C3b  0.59–1.6 SPR 10 mM HEPES with 150 mM NaCl, EDTA and surfactant, pH 7.4 Schmidt et al. (2008)
rFH  and FH–C3b 1.5–2.9 SPR 10 mM HEPES with 150 mM NaCl, Mg  and surfactant, pH 7.4 Schmidt et al. (2011)
FH–C3u 0.11 SV PBS with 50 mM NaCl, pH 7.4 Li (2010)
FH–C3u 0.59 SV PBS with 137 mM NaCl, pH 7.4 Li (2010)
SCR-1/4–C3b 11 SPR PBS with 150 mM NaCl and surfactant, pH 7.4 Wu  et al. (2009)
SCR-1/4–C3b 9.8–13.5 SPR 10 mM HEPES with 150 mM NaCl, EDTA and surfactant, pH 7.4 Schmidt et al. (2008)
SCR-19/20–C3b 5.4 SPR PBS with 140 mM NaCl, pH 7.3 Jokiranta et al. (2006)
SCR-19/20–C3b 3.5–4.5 SPR 10 mM HEPES with 150 mM NaCl, EDTA and surfactant, pH 7.4 Schmidt et al. (2008)
SCR-19/20–C3b 0.54 SPR 10 mM HEPES with 150 mM NaCl, EDTA and surfactant, pH 7.2 Kajander et al. (2011)
SCR-15/20–C3d 0.088 SPR Veronal with 75 mM NaCl, pH 7.4 Hellwage et al. (2002)
SCR-16/20–C3d 1.0 SPR 10 mM HEPES with 50 mM NaCl, pH 7.4 Okemefuna et al. (2009a,b)
SCR-16/20–C3d 2.6 SPR 10 mM HEPES with 137 mM NaCl, pH 7.4 Okemefuna et al. (2009a,b)
SCR-19/20–C3d 0.18 SPR 10 mM HEPES with 150 mM NaCl, EDTA and surfactant, pH 7.2 Kajander et al. (2011)
SCR-19/20–C3d 6.2–8.2 SPR 10 mM HEPES with 150 mM NaCl, Mg  and surfactant, pH 7.4 Morgan et al. (2011)
FH–heparin interactions
FH–commercial heparin 0.0092 SPR PBS with 50 mM phosphate, 100 mM NaCl, pH 7.2 Yu et al. (2007)
SCR-19/20–heparin dp4 9.0 NMR  20 mM acetate with 200 mM NaCl, pH 4.0 Herbert et al. (2006)
SCR-6/8 (His402)–heparin dp10 <14b SV PBS with 137 mM NaCl, pH 7.3 Fernando et al. (2007)
FH–heparin dp30/dp36 ∼0.5 SV 10 mM HEPES with 137 mM NaCl, pH 7.4 Khan (2011)
FH–CRP interactions
CRP–Ca 60 ED 50 mM Tris, 100 mM NaCl, pH 7.5 Kinoshita et al. (1989)
CRP–Ca  30 SPR 10 mM HEPES, 100 mM NaCl, pH 7.4 Christopeit et al. (2009)
CRP–CRP 19 SV 10 mM Tris, 50 mM NaCl, 2 mM CaCl2, pH 8.0 Okemefuna et al. (2010a)
CRP–CRP 16–26 SPR, SAXS 10 mM Tris, 140 mM NaCl, 2 mM CaCl2, pH 8.0 Okemefuna et al. (2010a)
FH–CRP 4.2 SPR 10 mM Tris, 137 mM NaCl, 2 mM CaCl2, pH 7.4 Okemefuna et al. (2010b)
SCR-6/8 (Tyr402)–CRP 3.9 SPR 10 mM HEPES, 137 mM NaCl, 2 mM CaCl2, pH 7.4 Okemefuna et al. (2010b)
SCR-6/8 (His402)–CRP 11.9 SPR 10 mM HEPES, 137 mM NaCl, 2 mM CaCl2, pH 7.4 Okemefuna et al. (2010b)
SCR-16/20–CRP 15.3 SPR 10 mM HEPES, 137 mM NaCl, 2 mM CaCl2, pH 7.4 Okemefuna et al. (2010b)
FH–zinc interactions
FH–zinc ∼10b SAXS 10 mM HEPES, 137 mM NaCl, pH 7.4 Nan et al. (2008b, 2011)
SCR-6/8–zinc ∼10b SAXS 10 mM HEPES, 137 mM NaCl, pH 7.4 Nan et al. (2011)
 equili
o
S
z
2
a
ﬂ
f
c
m
2
t
S
K
S
2
i
u
a
u
n
a
ba ED, equilibrium dialysis; SAXS, small-angle X-ray scattering; SE, sedimentation
b The KD value was estimated from the protein or ligand concentrations in use.
f FH (Schmidt et al. 2008). There are CRP binding sites within
CR-6/8 and SCR-16/20 of FH (Okemefuna et al. 2010b).  Weak
inc binding sites are mostly located within SCR-6/8 (Nan et al.
011). The absence of a high resolution crystal structure for FH is
ttributable to its large size, glycosylation and presumed inter-SCR
exibility. To compensate for this, folded-back solution structures
or intact FH at medium structural resolution were determined by a
ombination of X-ray scattering, analytical ultracentrifugation and
olecular modelling (Aslam and Perkins 2001; Okemefuna et al.
009a). At present, a total of 14 high resolution SCR structures of
he 20 are known, using crystallography for SCR-1/4, SCR-6/8, and
CR-19/20 (Jokiranta et al. 2006; Prosser et al. 2007; Wu et al. 2009;
ajander et al. 2011; Morgan et al. 2011), and NMR  for SCR-1/3,
CR-5, SCR-7, SCR-12/13, SCR-15/16 and SCR-19/20 (Hocking et al.
008; Schmidt et al. 2010). Eleven of these structures have been
ncorporated in the latest full length FH model, which has been
pdated further (Fig. 1b) (Okemefuna et al. 2009a; Nan et al. 2010).
Biophysical methods for looking at the quantitative FH inter-
ctions with itself and with four ligands include analytical
ltracentrifugation, X-ray scattering and surface plasmon reso-
ance. The KD values of the interactions can be obtained from
ll three methods. In addition, structural information can also
e obtained from ultracentrifugation and scattering. The velocitybrium; SPR, surface plasmon resonance; SV, sedimentation velocity.
method in ultracentrifugation involves sample sedimentation at
high rotor speeds, and analyses of the boundaries measured with
time lead to the size distribution function c(s). Ultracentrifuga-
tion is more powerful than the other two  methods because the
presence of multiple species in the sample is revealed by sepa-
rate peaks with their sedimentation coefﬁcients s20,w in the c(s)
analyses (after correction to 20 ◦C and the density of water). The
KD values are obtained from integration of these individual c(s)
peaks (Okemefuna et al. 2010a).  The classic sedimentation equilib-
rium approach also leads to KD values by the ﬁts of sedimentation
curves recorded at equilibrium for different concentrations and
rotor speeds (Nan et al. 2008a).  Scattering measures the diffrac-
tion from protein solutions. If scattering is used for determining KD
values, the scattering curves need to be known for the unbound
structures as well as for the complex (Okemefuna et al. 2010a,b).
From these, the ratio of the unbound and complexed species can be
determined by ﬁts of scattering curves measured in a concentration
range. Surface plasmon resonance is used to study the on-rate and
off-rate of a soluble “analyte” ﬂowed over and binding to an immo-
bilised interaction partner (the “ligand”). If these rates are slow
enough, the ratio of the off-rate/on-rate gives the KD value. If these
rates are rapid, the response unit values of the bound analyte mea-
sured as a function of its concentration given an association curve
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Fig. 2. Self-association of FH by analytical ultracentrifugation. The sedimentation velocity c(s) distribution analyses are shown for four FH proteins. For the SCR-1/5 fragment
in  (a), a single s20,w peak is seen at 2.4 S, indicating monomer. For SCR-6/8 (His402) in (b), two s20,w peaks are seen at 2.0 S and 3.2 S, indicating a predominant monomer
and  small amounts of dimer. For SCR-16/20 in (c), two  s20,w peaks are seen at 2.9 S and 3.8 S, indicating both monomer and dimer. In (d) for wild-type FH at 5.9 mg/ml, a
more  rapidly sedimenting component is seen at the top of the boundaries, while in (e) this feature is less apparent for FH at 0.17 mg/ml. In (f), in the ﬁve c(s) analyses for FH
between 0.17 mg/ml  and 5.9 mg/ml, the monomer peak is denoted by 1, and the FH oligomers are labelled from 2 to 7. In these c(s) plots, the FH dimer (peak 2) reaches 7%
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dapted from Fernando et al. (2007), Okemefuna et al. (2008) and Nan et al. (2008a
rom which the KD value is obtained (Okemefuna et al. 2010a,b).
he use of all three methods together is advantageous to reduce the
xperimental uncertainties inherent by the use of a single method.
elf-association of Factor H
A molecular understanding of the FH interactions with its lig-
nds requires the KD values for each FH–ligand complex. Given that
H self-associates with a M KD value that is comparable to the KD
alues for its FH–ligand complexes (Table 1), an understanding of
H self-association is relevant to FH–ligand studies. Accurate FH
oncentrations are required for KD determinations. There are lit-
rature discrepancies in the determination of FH concentrations
rom 280 nm absorbance measurements. The original FH sequence
howed that ﬁve of the nine putative N-glycosylation sites in FH
ere occupied, together with one more of the three remaining sites,
nd that SCR-4 was not glycosylated (Ripoche et al. 1988). It is now
nown from mass spectrometry that eight of the nine glycosylation
ites in FH are occupied, and the non-glycosylation of SCR-4 was
onﬁrmed (Fig. 1a) (Fenaille et al. 2007). From this knowledge andthe FH sequence, the FH molecular mass is calculated as 154.4 kDa
and the predicted FH absorption coefﬁcient at 280 nm (1%, 1 cm
path length) is revised to be 16.2 (Perkins 1986). The latter is high
for reason of the conserved Trp residue found in most SCR domains.
Other groups work with a 20% higher absorption coefﬁcient of 19.5
(Hakobyan et al. 2008) or a 12–23% lower value of 14.2 or 12.4 (Sim
and DiScipio 1982; Pangburn et al. 2009). A value of 16.0 is used
by the Edinburgh group (Schmidt et al. 2011). The value of 16.2
used in our work is conveniently close to the mean of the three
experimental determinations.
The self-association property of FH was ﬁrst quantitatively iden-
tiﬁed by X-ray scattering in 1991 (Perkins et al. 1991). At the
comparatively high FH concentration of 2 mg/ml (13 M),  the FH
molecular weight was almost doubled when this was compared
to the scattering intensities from standards. Self-association was
disputed when DiScipio (1992) argued from the single peak seen
by gel ﬁltration and single electron microscopy images of FH that
FH was monomeric; that study did not consider the possibility
of an equilibrium between monomer and dimer forms. Scatter-
ing studies of gel-ﬁltered FH in a wide range of concentrations
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Fig. 3. Self-association of FH by surface plasmon resonance. (a) The ligand was  150 RU of wild-type heterozygous FH immobilised on a CM5  chip. The analyte was a
homozygous FH Tyr402 sample at seven concentrations between 0 M and 9.7 M in 10 mM HEPES, 137 mM NaCl buffer, pH 7.4. (b) The binding afﬁnity was ﬁtted to a 1:1
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aken from Nan et al. (2010).
f 0.7–14 mg/ml  (5–90 M)  also suggested monomer (Aslam and
erkins 2001). The FH monomer issue appeared to be settled until
ore sensitive scattering and ultracentrifugation experiments with
he FH SCR-6/8 fragment revealed a monomer–dimer equilibrium
ith a KD of 40 M (Fig. 2b) (Fernando et al. 2007). The FH SCR-
6/20 fragment also showed a monomer–dimer equilibrium with
 KD of 16 M (Fig. 2c) (Okemefuna et al. 2008). No dimer was  seen
or SCR-1/5 (Fig. 2a) (Okemefuna et al. 2008), while the deglycosy-
ated SCR-12/13 fragment showed 20% dimer formation (Schmidt
t al. 2010). Even though self-association may  be artefactual, pos-
ibly caused by working with fragments or deglycosylation, the
bservation of dimerization in SCR-6/8 and SCR-16/20 prompted
he re-examination of native FH. The possibility of at least two  dif-
erent self-dimerisation sites in FH led to the prediction that an
ndeﬁnite set of FH oligomers could be formed through the alter-
ate daisy-chaining of these dimerization sites. The presence of FH
onomers and dimers and smaller amounts of larger species rang-
ng up to heptamers was directly conﬁrmed using size-distribution
nalyses c(s) of the sedimentation velocity data (Fig. 2d–f). The c(s)
nalyses comprised a new ultracentrifugation method that success-
ully resolved these FH oligomers (Nan et al. 2008a). The molecular
odelling of FH oligomeric structures veriﬁed the observed sedi-
entation coefﬁcients of these s20,w peaks 2–7. At the same time,
mprovements in X-ray scattering technology enabled small FH
oncentration dependences between 1 and 5 mg/ml  to be identiﬁed
hat were missed in the Aslam and Perkins (2001) study. Overall,
edimentation equilibrium showed that, below 1 mg/ml, FH could
e ﬁtted as a reversible monomer–dimer equilibrium with a KD of
8 M (Nan et al. 2008a). Above 1 mg/ml  FH, as evidenced by gel
ltration of stored FH, oligomer formation became irreversible.
The question arises of whether FH self-association seen in the
est-tube also occurs in plasma. In typical 0.2–0.8 mg/ml  plasma
oncentrations of FH, the KD value of 28 M means that 5–14% of
H will be dimeric and higher if no other factors inﬂuence this equi-
ibrium. The stability of these FH oligomers was therefore tested
y variation of the buffer. The use of different NaCl concentrations
50 mM,  250 mM)  and different pH 3 and pH 9 conﬁrmed that these
H oligomers existed in all these conditions, with more oligomer
eing seen in low salt (Okemefuna et al. 2009a).  Conformational
hanges in FH were also detected, when its overall length increased
ith NaCl concentration. Thus FH self-association is a robust prop-
rty that is likely to prevail in the 70 mg/ml  environment of plasmaM with a 2 value of 2.6 RU2 (vertical dashed straight lines).
proteins at pH 7.4. The literature showed a varied acceptance of FH
self-association. Thus the Jena group reported FH self-association
with SCR-1/7 using surface plasmon resonance (Oppermann et al.
2006). The Helsinki group saw dimers of FH SCR-15/18 and SCR-
15/20 by non-reducing SDS-PAGE and in the crystal structure of
SCR-19/20, although dimers seen in a crystal would not gener-
ally be regarded as evidence for dimerization in solution (Jokiranta
et al. 2000, 2006). The Texas group noted some propensity for self-
association by sedimentation equilibrium (Pangburn et al. 2009).
In distinction, the Edinburgh group did not see dimer in SCR-19/20
by NMR  (Herbert et al. 2006), although NMR  is insensitive to dimer
formation. The Edinburgh group also reported FH at 1 mg/ml to be
monomer by dynamic light scattering “with little propensity to self-
associate” (Schmidt et al. 2011), although light scattering is unable
to resolve monomer and dimer if their overall shapes are similar
(Nan et al. 2008a).
The proper interpretation of FH–ligand experiments requires
allowance for FH self-association. Even though this will poten-
tially complicate data interpretation, it can sometimes simplify
these. Given that the main evidence for FH self-association is from
the ultracentrifugation c(s) analyses and scattering concentration
dependences, other methods have now been used to strengthen
the evidence for FH self-association. Thus, FH oligomers have
been seen using homozygous FH from genotyped donors (Nan
et al. 2010, 2011), hence ruling out heterozygosity as the cause of
oligomers. Mass spectrometry also revealed FH dimers and trimers.
Surface plasmon resonance showed that homozygous FH in solu-
tion self-associated with immobilised heterozygous FH with a KD
value of 8 M,  although our subsequent more detailed studies
(unpublished) show that the actual KD value is larger (Fig. 3). FH
self-association is summarised in Fig. 4a.
Interactions of Factor H with the C3 proteins
C3 (190 kDa) at 1.3 mg/ml  (7 M)  is the central complement
protein, and its plasma concentration rises by 50% in acute phase
conditions. During circulation in blood, the thioester group in
C3 is slowly hydrolysed to form C3u, alternatively known as
C3(H2O). C3u participates in C3 convertase formation to enable
C3 to be rapidly cleaved to functionally active C3b and a small
anaphylatoxin C3a. Cleavage induces a conformational change in
this compact 13-domain protein, in which C3d (the TED domain)
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Fig. 4. Cartoon of FH, C3 and CRP self-association. The current understanding of self-association is depicted, following the colour scheme in Fig. 1b. (a) A putative FH dimer is
shown that self-associates through two dimer sites at SCR-6/8 and SCR-16/20. Higher FH oligomers can form through the daisy-chaining of these dimer sites. Adapted from
Fernando et al. (2007), Okemefuna et al. (2008) and Nan et al. (2008a,b). (b) Schematic domain diagrams for C3, C3u and C3b that show the different positions of the TED and
CUB  domains in these three proteins. The ANA domain present in C3 and C3u but not in C3b is also shown. Both C3 and C3u form back-to-back dimers with a KD of 46 M
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Fig. 1b) moves from one end of the C3 structure to the other end
o expose an internal thiolester group within this domain (Janssen
t al. 2005). This exposed thioester of C3b is able to form a cova-
ent bridge with pathogenic and host cell surfaces to label these
or complement attack. C3b bound to host cells is inactivated by
actor I protease with FH as the regulatory cofactor to result in the
leavage of C3b to form the TED domain (also known as C3d) and
3c. C3b itself dimerises with the Bb protease fragment of Factor
 to form the C5 convertase. High resolution crystal structures are
nown for C3, C3a, C3b, C3c and C3d and their macromolecular
omplexes with ligands such as FH SCR-1/4, Factor B and comple-
ent inhibitors (Gros et al. 2008; Rooijakkers et al. 2009; Forneris
t al. 2010). The solution properties of the C3 proteins and their
nteractions with ligands such as FH are less well known.esembles the self-association of C3d (TED domain) in the same buffer (data in red
ers through contacts between its A-faces. Adapted from Okemefuna et al. (2010a).
 the web  version of the article.)
The C3d fragment shows salt-dependent oligomeric proper-
ties. In low salt (50 mM NaCl buffer), X-ray scattering showed
concentration-dependent RG values that initially suggested a
monomer–dimer KD value of 23 ± 3 M (Table 1) (Gilbert et al.
2005; Perkins and Furtado 2005). Scattering modelling resulted
in good curve ﬁts for monomers at low concentrations when
dissociation into monomers had occurred (Gilbert et al. 2005).
Subsequent analytical ultracentrifugation c(s) analyses and sed-
imentation equilibrium ﬁts showed that, in 50 mM  NaCl, C3d
exhibited a monomer–dimer–trimer equilibrium rather than a
monomer–dimer equilibrium (Li et al. 2008). In fact, the s20,w val-
ues suggest that a monomer–dimer–tetramer equilibrium cannot
be ruled out (Figs. 4b and 5b). In contrast, in physiological 137 mM
NaCl buffer, C3d is observed to be monomeric only in c(s) plots.
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Fig. 5. Multimerisation of C3, C3u and C3d. The sedimentation velocity c(s) distribution analyses are shown for three C3-related proteins. (a) The c(s) distributions for C3 and
C3u  in 137 mM (left) and in 50 mM (right) NaCl buffers. A major C3 monomer s20,w peak is visible at 7.85 S in 137 mM NaCl, which is shifted to 8.02 S in 50 mM NaCl. This peak
is  unchanged with concentration in 137 mM NaCl, but shifts with concentration in 50 mM NaCl. A second s20,w peak corresponding to discrete C3 dimers is visible at 11.2 S.
A  major C3u monomer s20,w peak is visible at 7.44 S in 137 mM NaCl, which is shifted to 7.66 S in 50 mM NaCl. This peak is unchanged with concentration in 137 mM NaCl,
but  shifts with concentration in 50 mM NaCl. A second s20,w peak corresponding to discrete C3 dimers is visible at 11.5 S. The change in sedimentation coefﬁcient between
C3  and C3u is shown by the vertical dashed lines. (b) The c(s) size distributions for C3d at 1.1 mg/ml and 3.7 mg/ml in 137 mM NaCl (left) and 50 mM NaCl (right) is shown.
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Cn  137 mM NaCl, a single species at 2.9 S is seen and was  designated as a monome
esignated as M (monomer), D (dimer) and T (trimer/tetramer) in increasing order
dapted from Li et al. (2008, 2010).
his outcome warns against the use of 50 mM NaCl for FH–C3
xperiments. Low salt is advantageous in promoting weak ionic
nteractions that will increase the amount of complex formed for
xperiments. However, low salt can promote binding artefacts,
ecause inappropriate ionic interactions become more signiﬁcant
nd can lead to non-physiological complex formation.
The oligomeric properties of C3 and C3u were likewise estab-
ished in both 50 mM and 137 mM NaCl buffers using analytical
ltracentrifugation and X-ray scattering (Li et al. 2010). The c(s) sed-
mentation coefﬁcient analyses identiﬁed two distinct dimerization
vents for each protein (Fig. 5a). A low amount of a fast dimer-
zation at 8 S, which leads to a concentration-dependent single
eak known as a reaction boundary, was observed only in 50 mM
aCl for C3 and C3u and not in 137 mM NaCl. Given that C3d is
quivalent to the TED domain, and shows the same salt-dependent
ehaviour as C3 and C3u, the fast dimerization is most likely to arise
rom self-association involving the TED domain (Fig. 4b). Minor
mounts of a second slow dimerization were observed for both
3u and C3 at about 11 S in both buffers. The monomer and dimer0 mM NaCl, two or three s20,w peaks are seen at 1.2 mg/ml  and 2.8 mg/ml, and are
alues.
s20,w peak intensities lead to a KD of 38 ± 16 M for C3u and C3
in 50 mM NaCl, and a KD of 46 ± 15 M for C3u and C3 in 137 mM
NaCl for this slow dimerization (Table 1). This second dimeriza-
tion event may correspond to the C3b dimer observed in one of
the C3b crystal structures (Fig. 4b). This C3b dimer is to be dis-
tinguished from the C3b dimer of the C5 convertase when one
C3b molecule binds to another C3b molecule through its thioester
group. The 11 S sedimentation coefﬁcient of this second dimer s20,w
peak was  validated by calculation using a C3b dimer seen in one of
the C3b crystal structures. The RG concentration dependences seen
by X-ray scattering supported the c(s) analyses, although scatter-
ing is not able to identify directly the oligomeric species that were
present. In further analyses, the molecular modelling of the scat-
tering curves showed that the TED/CUB domains in monomeric
C3u were extended into solution. This TED/CUB conformation is
intermediate, but distinct from, that between those found in C3
and C3b (Fig. 4b). In reﬂection of this conformational change, the
sedimentation coefﬁcients of C3u are slightly lower than those
of C3 (Fig. 5a).
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Fig. 6. Interaction between SCR-16/20 and C3d by analytical ultracentrifugation. The s20,w peaks 1 and 3 correspond to the monomer and dimer of SCR-16/20 (Fig. 2c). The
s20,w peaks 2, 4 and 5 in 50 mM NaCl correspond respectively to the monomer, dimer and putative trimer/tetramer from C3d (Fig. 5b). (a) The c(s) analyses from experiments
in  50 mM NaCl buffer with mixtures of SCR-16/20 and C3d showed two extra peaks 6 and 7 at large S values at low stoichiometric ratios, to be replaced by three peaks 6, 7
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dapted from Okemefuna et al. (2009a,b).
FH binds to two dominant different locations in C3b, with one
3b site at SCR-1/4 and the other C3b site at SCR-19/20 (Schmidt
t al. 2008). The SCR-1/4 site in C3b lies between the CUB/TED
omains and the MG  domains (Fig. 1b). FH also binds C3d at the SCR-
9/20 site (Bhattacharjee et al. 2010). Biophysical solution studies
f these interactions were initiated with the SCR-16/20 fragment
nd C3d, and working with both 50 mM and 137 mM NaCl buffers
Okemefuna et al. 2009b). Ultracentrifugation showed that as many
s eight s20,w peaks were observed in both buffers in the size dis-
ribution c(s) plots on mixing C3d with SCR-16/20 (Fig. 6), even
hough only three s20,w peaks were expected for the two  unbound
roteins and their complex. This outcome showed that the C3d–FH
nteraction site does not block the interaction sites responsible for
he formation of C3d oligomers, unlike the case of the CR2 SCR-1/2
omplex with C3d (Gilbert et al. 2005). The concentration depen-
ence of the eight s20,w peaks, such as peak 6 in Fig. 6b, showed that
he interaction was a weak one with comparatively rapid on/off
ates. At that time, by assuming a monomer–dimer equilibrium for
ach of SCR-16/20 and C3d, the eight s20,w peaks were originally
xplained in terms of putative C3d dimers and SCR-16/20 dimers
hat associated in alternation with each other to form oligomers
ith stoichiometries of 1:1 to 8:8. The occurrence of multimers
as conﬁrmed by surface plasmon resonance. Thus KD values of
 M and 2.4 M were determined in 50 mM and 137 mM NaCl
espectively for a 1:1 complex of C3d and SCR-16/20. Further inten-
ity changes were seen at higher C3d analyte concentrations that
eﬂected higher multimerisation. The two recent crystal structures
f the C3d–SCR-19/20 complex now clarify these results (Kajander
t al. 2011; Morgan et al. 2011), although neither study acknowl-
dged our 2009 surface plasmon resonance and ultracentrifugation
tudy of this interaction. The Helsinki crystal structure reported a
:1 complex with two C3d bound per SCR-19/20 at two  distinct sites
n SCR-19/20. Our observation of eight peaks for the SCR-16/20
nd C3d mixtures may  be explained in terms of a series of elevenat, although the peaks 4 and 5 from C3d have disappeared (Fig. 4), peaks 6, 7 and 8
distinct monomers and oligomers deduced from that crystal struc-
ture (ten are shown in Fig. 7b). The Edinburgh crystal structure
revealed only a 1:1 complex between C3d and SCR-19/20, and this
leads to a prediction of eight distinct monomer and oligomer forms
for the C3d mixture with SCR-16/20.
The 2009 FH–C3d study provided insight into complement reg-
ulation. After host-cell bound C3b is inactivated by Factor I cleavage
into C3c and C3d, C3d will be left bound through its thioester
group to the host cell surface. When C3b activation levels are high,
larger amounts of C3b will be deposited and inactivated on host
cell surfaces, hence increasing the amount of available C3d. Con-
sequently host cells will present signiﬁcant levels of C3d-coated
surfaces. Equivalent high levels of C3d will not be formed on for-
eign cells because FH is not expected to bind to their surfaces. The
ability of C3d and FH to form multimeric complexes at host cell
surfaces will enable even more FH to bind to host cells in order to
offer additional complement regulatory protection under chronic
inﬂammatory conditions.
FH–C3b complex formation will be incomplete in plasma. When
C3 is activated to C3b in body ﬂuids, only small amounts of C3b
will form. The C3b concentration is expected to be low at g/ml
levels (0.1 M).  It could be argued that the “local” C3b concentra-
tion might be quite high over a very short period. However it is
not possible that equimolar amounts of 0.8 mg/ml FH and 1 mg/ml
C3b (5 M)  will co-exist in vivo. The KD values for the FH–C3b and
FH–C3u interactions lie in a range of 0.59 to 2.9 M in 137–150 mM
NaCl (Table 1). If theoretically equimolar amounts of FH (0.8 mg/ml)
and C3b/C3u (1 mg/ml) occur at 5 M in plasma, 48–71% of com-
plex will be formed, meaning that a signiﬁcant proportion of FH
and C3b/C3u will be uncomplexed. If FH is at 5 M and C3b is at
0.1 M,  much lower levels of 2% complex will be formed. Stronger
complex formation occurs in 50 mM NaCl, showing the role of elec-
trostatic forces in stabilising the complex (Table 1). This result
for FH is conﬁrmed by the FH fragments. Two  studies of SCR-1/4
290 S.J. Perkins et al. / Immunobiology 217 (2012) 281– 297
Fig. 7. Cartoon of FH interactions with its ligands. The current understanding of how FH interacts with its major ligands is depicted. (a) C3u or C3b will bind to SCR-1/4, and
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tself  around C3b to form a 1:1 complex. (b) SCR-16/20 and C3d interact with each 
utline  of possible complexes based on C3d binding to each of SCR-19 and SCR-20 i
 2:2 complex is formed (peak 2 in Fig. 8b) as well as others.
inding to C3b gave comparable KD values in a range of 9.8–13.5 M
Table 1), indicating that 5 M of SCR-1/4 would only be 22–27%
ound to C3b. Three studies of SCR-19/20 binding to C3b gave com-
arable KD values in a range of 0.54–5.4 M (Table 1), indicating
hat 5 M of SCR-19/20 would only be 37–72% bound to 5 M C3b.
imilar KD ranges are seen also for SCR-19/20 binding to C3d in
37–150 mM NaCl (Table 1). Even though there can be a 2-fold to
0-fold variability in the individual KD values measured in differ-
nt laboratories, this variability is attributable to the chip surface
sed for measurements and the use of different protein prepara-
ions, which can alter between laboratories or even within them
Morgan et al. 2011). The overall view of these three single-site or
ouble-site FH interactions is that only about 50% FH–C3b complexn with a 2:1 stoichiometry. Many groups consider that one molecule of FH wraps
to form a series of multimers that are seen in the c(s) analyses (Fig. 6). A schematic
n. (c) FH interacts with anionic oligosaccharides at SCR-7 and SCR-20. In solution,
is expected to be formed at best in body ﬂuids. In plasma/serum,
C3b is broken down very quickly to iC3b, indicating that a C3b–FH
complex has formed. Kinetics are important here: it was  not pos-
sible to include extensive kinetic analysis in this review, but the
potential importance of the fast on/off rates for the FH–C3b com-
plex are consistent with the M KD values. In addition, given that
there is no major enhancement in the KD value for intact FH com-
pared to those for the FH fragments, this suggests that the two C3b
binding events may  be independent of each other (Fig. 7a). Elec-
tron microscopy suggested that C3b only binds to one end of FH
(DiScipio 1992). In distinction, much of the FH–C3b literature dis-
cuss alternative structural models in which FH becomes wrapped
around C3b in a 1:1 complex, the contacts being mediated by both
obiology 217 (2012) 281– 297 291
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Fig. 8. FH–heparin interaction by analytical ultracentrifugation. (a) FH at 1.08 mg/ml
(7  M)  was studied in the presence of a 1:1 molar ratio of dp30. The experimental
velocity scans are shown in black, and the ﬁts are shown in white. A more rapid
sedimentation is observed at the top of the scans that corresponds to the FH–heparin
oligomers. (b) The c(s) analyses for FH alone and the FH–dp30 heparin mixture are
shown. The FH monomer s20,w peak is labelled as 1, and the FH oligomer s20,w peaks
(dimer onwards) are denoted by 2–12 in increasing order of S values. The change
in  the sedimentation coefﬁcients for peaks 2, 3 and 4 between FH and FH–dp30 isS.J. Perkins et al. / Immun
CR-1/4 and SCR-19/20 in intact FH (Kajander et al. 2011; Morgan
t al. 2011).
nteraction of Factor H with heparin
FH regulates surface-bound C3b activity on host cells by recog-
ising polyanionic structures such as heparan sulphate on these
urfaces, thereby inhibiting complement activation. Heparin is
n analogue of heparan sulphate. Heparin fragments of sizes
p6–dp36 (dp: degree of polymerisation, corresponding to 3–18
duronate and glucosamine disaccharide units) have a semi-rigid
nd extended conformation that is pre-formed and optimal for
inding to protein targets such as FH without major conformational
hanges (Fig. 1) (Khan et al. 2010). These heparin solution struc-
ures became progressively more bent with increased size. Heparan
ulphate fragments dp6–dp24 have also been studied in a predom-
nantly unsulphated form. The smaller ones dp6–dp16 revealed
 longer and more bent structure than heparin. The longer ones
p18 and dp24 exhibited multiple structures and a higher degree
f ﬂexibility than the corresponding heparin fragments (Khan et al.
011).
Heparin is often used as an analogue for heparan sulphate, and
nteracts with FH primarily at SCR-7 and SCR-20 (Fig. 1). The ﬁrst
stimates of KD values in 50–100 mM NaCl buffer suggested values
f 9 M or 9.2 nM (Table 1). The FH SCR-6/8 fragment showed a
ent SCR domain arrangement that binds heparin dp10 tightly in
37 mM  NaCl buffer by ultracentrifugation c(s) analyses (Fernando
t al. 2007). This tight binding placed an upper limit of 14 M for
he KD for the SCR-6/8 interaction with dp10. X-ray scattering sug-
ested that SCR-6/8 with dp10 changed conformation or formed
ligomers. This work was extended to full-length FH by studying
he effects of dp6–dp36 using 1:1 mixtures of FH–heparin by X-
ay scattering and analytical ultracentrifugation (Khan 2011). The
-ray radius of gyration RG of FH decreased slightly for dp6 and
p12, which is explained by the removal of FH self-association
hrough heparin binding. Since the FH monomer–dimer KD value
s 28 M,  this shows that the KD for the FH–heparin interaction
s below 28 M.  With dp18–dp36, the RG values increased, and
he scattering curves showed that compact FH–heparin oligomers
ad formed. The results were conﬁrmed by ultracentrifugation,
hen the 12–15% of FH oligomers became 61–63% oligomers
ith dp30–dp36 (Fig. 8a). The c(s) peaks ranged from dimeric to
ecameric FH–heparin complexes with sedimentation coefﬁcients
hat were smaller than those for FH to indicate that larger struc-
ures had been formed with heparin (Fig. 8b). The 61–63% of FH
ligomers correspond to a KD value of about 0.5 M for the interac-
ion with dp30 and dp36. In addition, computer modelling showed
hat no major conformational change in FH occurred when FH
as crosslinked by heparin to form dimeric, trimeric, tetrameric
nd pentameric rings. Instead, heparin inserted itself between FH
olecules to form larger structures (Fig. 7c). Thus at M concen-
ration levels of FH in plasma, FH is able to interact with heparin at
wo independent sites.
In theory, the combination of two separate FH–heparin weak
inding events with M KD values on the one molecule will become
 higher afﬁnity with an overall KD of pM (the product of the two
ndividual KD values) (Jencks 1981). In practice, a full enhance-
ent in afﬁnity is not seen. Nonetheless, depending on the surface
ensity of heparin-like structures and the ﬂexibility of FH, the inde-
endent binding of both heparin sites on FH to a single host cell
urface will strengthen the overall interaction. Therefore the biva-
ency of the FH–heparin interaction would be a major advantage for
ts regulatory role. Bivalency would facilitate the selective binding
f FH to host cells so long as the host cells displayed multimericshown by the vertical dashed lines.
Adapted from Khan (2011).
polyanionic surfaces with an appropriate density of binding sites,
unlike the pathogens that lack these multiple sites.
The relationship of heparin binding to disease remains to be
elucidated in detail. Curiously, AMD  is genetically related with a
defective SCR-6/8 binding site, while aHUS is related with a defec-
tive SCR-19/20 binding site. In the context of AMD, three studies
reported a higher afﬁnity of heparin for the FH Tyr402 allotype
compared to His402 (Herbert et al. 2007; Skerka et al. 2007; Ormsby
et al. 2008). This implies that the weaker binding of FH His402 to
host cell surfaces predisposes to AMD. A fourth study reported vari-
able outcomes depending on the heparin preparation in use and
its degree of sulphation (Clark et al. 2006). A ﬁfth study reported
292 S.J. Perkins et al. / Immunobiology 217 (2012) 281– 297
Fig. 9. Self-association of CRP by three methods. All the buffers contained 2 mM Ca2+ and 140 mM NaCl. (a) By analytical ultracentrifugation in solution, the pentamer and
decamer forms were observed as two s20,w peaks, one at 6.4 S that corresponds to CRP pentamer at 0.2 mg/ml, and one at about 8 S that is a reaction boundary corresponding
to  a rapid equilibrium between pentameric and decameric CRP at 2.0 mg/ml. (b) By X-ray scattering, the experimental scattering curve at 2.7 mg/ml (upper) is a mixture of
4 tinuous lines). Fits of the lower two curves based on nine CRP concentrations gave a KD
v lyte was  ﬂowed over immobilised CRP. The equilibrium analyses showed that saturation
w sorgram showed that the on- and off-rates were rapid.
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Fig. 10. Ultracentrifugation of FH, CRP and their complex. The c(s) size-distribution
analyses showed that free FH and CRP each formed oligomeric species, and these
disappeared on mixing FH and CRP in buffers containing 2 mM Ca2+ and 140 mM
NaCl. The data for FH at 1.0 mg/ml showed monomer (peak 1) and small amounts
of dimer, trimer and tetramer (peaks 2–4) that are visible on the scale shown. The
data for CRP at 1.2 mg/ml showed pentamer (P) and decamer (D). The 1:1 molar1%  of the CRP pentamer curve and 59% of the CRP decamer curve (lower two con
alue of 16 M for the equilibrium. (c) Using surface plasmon resonance, a CRP ana
as  approached from which a KD value of 23 M was determined (Table 1). The sen
o signiﬁcant binding difference between the Tyr402 and His402
llotypes (Yu et al. 2007).
nteraction of Factor H with C-reactive protein
CRP has ﬁve lectin-like subunits arranged as a ﬂat disk with A-
nd B-faces. During the acute phase reaction, the plasma concen-
ration of CRP (molecular mass 115 kDa) increases rapidly by over
000-fold from 800 ng/ml in normal plasma to 0.5 mg/ml  (from
 nM to 4.4 M).  CRP binds ligands in a Ca2+-dependent manner
hat reﬂects the 2.5 mM Ca2+ present in plasma (Hurwitz 1996).
RP binds to phosphorylcholine, as well as phosphoethanolamine,
icrobial surface proteins, chromatin and other ligands (Pepys and
irschﬁeld 2003). Ca2+ and phosphorylcholine bind to the B-face of
RP. These CRP–ligand interactions lead to the labelling of damaged
r apoptotic cells and bacterial pathogens for recognition purposes.
RP activates the classical pathway of complement by binding to
1q at the A-face of CRP (Thompson et al. 1999). A FH–CRP inter-
ction would be important if this regulates complement activation
t CRP-coated damaged host cell surfaces.
The unravelling of the FH–CRP interaction was  complicated
y (i) FH self-association, (ii) CRP self-association (Fig. 4c), (iii)
RP denaturation, (iv) FH and CRP concentrations; (v) buffer com-
osition. Prior to our re-investigation of this FH–CRP interaction
Okemefuna et al. 2010a,b), nine out of 11 earlier studies had con-
luded that FH and CRP formed a physiologically relevant complex,
hile two studies concluded that complex formation only occurred
ecause denatured CRP was present. A critical evaluation of these
1 studies showed that the full physiological FH and CRP concentra-
ion range in plasma had not always been employed, 50 mM NaCl
uffer and not 140 mM NaCl had sometimes been used, 2 mM Ca2+
ad often been omitted from the buffer or was not speciﬁed, and
wo very different KD values of about either 1 M or 0.01 M were
easured previously for the same FH–CRP interaction.
The discrepancies in these 11 earlier FH–CRP studies now appearo be resolved (Okemefuna et al. 2010a,b). FH self-association
ith a monomer–dimer KD value of 28 M was  noted above
Table 1). A CRP pentamer–decamer association with a comparable
D value of 16–26 M in 140 mM NaCl (Table 1) was  identiﬁed by
ratio mixture of FH and CRP showed that new peaks A, B and C formed at different
S  values from those of peaks 1, 2, 3, P and D, whereupon the higher oligomers of FH
and  CRP disappeared.
Adapted from Okemefuna et al. (2010b).
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Fig. 11. Cartoon of three major FH interactions with host cell surfaces. The colour
scheme follows that in Fig. 1b. (a) FH binds to heparan sulphate-coated host cell
surfaces (represent here by heparin) through sites close to SCR-7 and SCR-19/20. This
FH  binding positions the SCR-1/4 domains in a conformation that binds readily to the
FH  binding site on C3b. The resulting C3b degradation to C3d and C3c will regulate
complement activation at host cell surfaces. (b) In conditions of inﬂammation, the
host  cells accumulate C3d on its surface. This bound C3d provides additional FH
binding sites that are able to recruit more FH to the host cell surface. This provides
additional regulatory control when C3 is present at elevated levels during the acute
phase response. (c) If the host cell surface is damaged and lipid is exposed, CRP
is  recruited to these host cells and binds wild-type FH (Y402) at both SCR-7 and
SCR-20. The FH SCR-1/4 domains are again appropriately located to mediate the
degradation of surface-bound C3b. (d) In contrast, FH (His402) is less able to regulate
C3b degradation because of the weaker binding of SCR-7 (His402) to CRP. This is
postulated to result in greater host cell damage. (For interpretation of the references
to  color in this ﬁgure legend, the reader is referred to the web version of the article.)S.J. Perkins et al. / Immun
ltracentrifugation c(s) analyses, X-ray scattering, and surface
lasmon resonance (Fig. 9). Interestingly, CRP aggregated with
mmobilised CRP in 50 mM NaCl, adding another cautionary note
bout the use of 50 mM NaCl buffer. Because Ca2+ binds to CRP with
 KD of 30–60 M (Table 1), 2 mM Ca2+ is required for full occu-
ancy of the calcium binding sites in CRP. When insufﬁcient Ca2+
s present, CRP partially dissociates into its protomers and dena-
ures. Denatured CRP has a higher afﬁnity for FH than native CRP,
nd this accounts for the low KD values of about 0.01 M for the
H–CRP interaction. In summary, a buffer with both 2 mM Ca2+ and
40 mM NaCl was essential for consistent results.
To clarify whether or not the FH–CRP interaction existed, FH
nd CRP mixtures were studied both in solution and on surfaces.
ltracentrifugation unexpectedly showed that the self-association
f FH and CRP in these mixtures was suppressed (Fig. 10). The size
istribution c(s) plot for the 1:1 mixture showed the s20,w peaks for
he expected unbound FH monomer and CRP pentamer, but with
he reduction of the s20,w peaks for the FH dimer (peak 2) and CRP
ecamer (peak D) and the removal of the peaks 3 and 4 for the
igher FH oligomers (Fig. 10). Two new peaks B and C appeared
n the c(s) plots. These were assigned to 1:1 and 2:1 complexes
f CRP with FH. CRP and FH binding was also observed using sur-
ace plasmon resonance with FH-immobilised or CRP-immobilised
hips respectively. Thus, using similar M FH and CRP concentra-
ions in the appropriate buffer, FH–CRP binding was determined to
ccur with a weak KD of 4 M (Okemefuna et al. 2010b).
Two CRP sites were identiﬁed in FH. This resembles the bind-
ng of FH to heparin (Fig. 11a) and to heparin and C3d (Fig. 11b).
his was veriﬁed using surface plasmon resonance, where each of
CR-6/8 and SCR-16/20 bound to immobilised CRP, but SCR-1/5 did
ot (Okemefuna et al. 2010b).  The removal of the FH dimers and
igher oligomers after adding CRP indicated that both the FH self-
ssociation sites were blocked by CRP. Here, a notable difference
n binding was seen between the wild-type allotype of SCR-6/8
Tyr402) and the AMD-risk allotype of SCR-6/8 (His402) SCR-6/8
inding to native CRP. The KD values were 4 M (Tyr402) and 12 M
His402). This difference provides molecular insight into an AMD-
ausative mechanism. In non-acute phase conditions, the resting
RP plasma concentration is low at 7 nM compared to FH at 7 M,
nd CRP–FH will not interact because the KD is 4 M.  During acute
hase conditions, there will be sufﬁcient CRP at 4.4 M to interact
ith FH. Excessive complement damage on CRP-decorated dam-
ged host cells would then be brought under regulatory control
hrough FH binding to CRP at SCR-6/8 and SCR-16/20 (Fig. 11c). If
he FH His402 allotype is present, this bivalent binding becomes
ess effective and FH is less able to regulate surface-bound C3b
n host cells (Fig. 11d). During successive acute-phase reactions
uring a lifetime, the accumulation of damage caused by such
 mechanism could contribute to the increased risk of AMD  for
ndividuals who are homozygous for FH His402. Interestingly, indi-
iduals who are homozygous for the FH His402 allotype show a
.5-fold higher level of CRP in the RPE, as to be expected from this
xplanation (Johnson et al. 2006).
nteraction of Factor H with zinc
The accumulation of high bioavailable zinc concentrations in the
ubretinal pigment epithelial deposits (drusen) of the outer retina
s associated with age-related macular degeneration (Lengyel et al.
007). Bioavailable zinc corresponds to zinc that is weakly bound
n vivo and therefore able to bind to targets with KD values in
M ranges. Both microprobe synchrotron X-ray ﬂuorescence and
uorescent zinc labels identiﬁed zinc concentrations as high as
00 ppm (several mM)  in drusen. Even though much of this zinc will
e tightly bound to proteins within drusen, the ﬂuorescent probesRedrawn from Okemefuna et al. (2010b).
prove the bioavailability of zinc. Elsewhere in the body, extracellu-
lar zinc levels as high as 300 M is reached in the synaptic cleft. In
plasma, zinc normally circulates at 12.5 M where zinc is usually
chelated. The KD for zinc binding to human serum albumin is 1 M,
and 84% of plasma zinc is bound to this protein (Lu et al. 2008).
Bioavailable plasma zinc occurs at 20–210 pM.  Interestingly FH reg-
ulation is inhibited by zinc, which causes FH to aggregate (Perkins
294 S.J. Perkins et al. / Immunobiolo
Fig. 12. The FH–zinc interaction by analytical ultracentrifugation. (a) The homozy-
gous Tyr402 FH allotype at 0.7 mg/ml  (5 M)  was titrated with zinc between 0.2 M
and  200 M.  In this sedimentation velocity experiment, only every tenth boundary
scan is shown for clarity. The rapid sedimentation of aggregates at the top compared
to  monomeric FH is clearly visible in the scans. (b) The averaged c(s) sedimentation
coefﬁcient distribution analyses from experiments at 20 M,  60 M and 120 M
zinc  are compared with each other. The FH monomer peak is close to 5.7 S. Lit-
tle  aggregation at 20 M zinc is seen. At 60 M and 120 M zinc, many more c(s)
peaks are seen between 20 S and 100 S. The zinc concentrations (M) are denoted
n
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FH complexes with its ligands are not fully formed; and (iii) sur-umerically.
dapted from Nan et al. (2011).
t al. 1991), and this observation prompted a further investigation
f the FH–zinc interaction.
Zinc-induced FH self-association was studied by X-ray scatter-
ng and analytical ultracentrifugation side-by-side with FH activity
ssays (Nan et al. 2008b).  Using physiological concentrations of
.42–1.05 mg/ml  pooled heterozygous FH (2.8–7.0 M), in the
bsence of phosphate which causes zinc to precipitate, FH was
naffected until [Zn] increased to over 10 M (Fig. 12a). The use of
10 M zinc triggered the strong aggregation of FH to form com-
act oligomers with ill-deﬁned s20,w peaks (Fig. 12b), showing that
he FH–zinc KD value is close to 10 M.  This KD value means that the
ioavailability of only 1% of the several mM zinc observed in drusen
s sufﬁcient to cause FH aggregation. Structurally distinct large FH
ligomers were also observed for copper. Fluid-phase assays with
inc and copper showed that the reduction of FH activity correlated
ell with the onset of oligomer formation. It was  concluded that
he weak binding of zinc to half-sites at the surface of FH caused
he cross-linking of the FH monomers to form oligomers (Fig. 13).
he implication of weak zinc binding to FH has not always been
ppreciated. Thus binding studies using radioactive zinc-65 with
lotted FH were interpreted to prove that FH did not bind zinc. The
eak M binding of zinc to FH means that any bound radioactive
inc would have been inadvertently removed by washing of the FH
lots prior to the radioactivity measurements (Blom et al. 2003).
Further zinc binding studies were performed in order to exam-
ne the interaction with homozygous FH (Tyr402 and His402) and
ts three functionally important recombinant fragments SCR-1/5,
CR-6/8 and SCR-16/20. In order to examine whether FH–zinc
ligomers are relevant to AMD, zinc titrations were performed
sing scattering and ultracentrifugation (Nan et al. 2011). Thegy 217 (2012) 281– 297
AMD-risk allotype introduces a His residue which is a poten-
tial zinc-binding residue. It turned out that both full-length FH
allotypes strongly aggregated again at zinc concentrations above
10 M (Fig. 12). Despite earlier clues that the His402 allotype might
bind more tightly to zinc than Tyr402, no detectable difference
between allotypes was  seen in the ﬁnal data analyses. The SCR-
6/8 allotypes both aggregated strongly with zinc, indicating that
the major zinc binding events occurred there. In comparison to
SCR-6/8, the zinc-induced aggregation of SCR-1/5 and SCR-16/20
was lower. Bioinformatics analyses predicted that the SCR-6/8
region had the highest propensity to bind zinc, in support of these
experiments. This leads to a schematic view of how zinc-induced
FH aggregation occurs to form oligomers (Fig. 13).  In conclusion,
these interaction studies showed that the zinc inhibition of FH–C3u
breakdown in the presence of Factor I is caused by SCR-6/8 aggrega-
tion within FH, suggesting that this aggregation sterically blocked
the binding of the neighbouring SCR-1/4 domains to C3u.
Conclusions and future considerations
A quantitative understanding of the incompletely formed
oligomeric and multivalent complexes formed by FH will permit
an understanding of the effect of FH polymorphisms and mutations
in causing diseases such as those of AMD  and aHUS. For the ﬁrst
time, we have a full set of KD values for the major FH–ligand com-
plexes (Table 1). The strongest FH interactions are formed by C3b
and C3u and these KD values are with low 1 M afﬁnities, mean-
ing that FH–C3b and FH–C3u complexes will not be fully formed
in plasma. The KD values for the SCR-1/4 and SCR-19/20 sites are
larger and similar (Schmidt et al. 2008). This makes it likely that two
molecules of C3b bind separately to FH without synergy between
the two sites (Fig. 7a), and there is evidence for this stiochiometry
(Li 2010). Ligands such as heparin (an analogue of heparan sulphate
on host cells) bind multivalently to FH at two independent sites
(Fig. 7c), each with afﬁnities of several M (Khan 2011). The mech-
anism by which double-binding of FH to heparin with an overall
afﬁnity below 1 M takes place enables FH to recognise appropri-
ate charge clusters at host cell surfaces. Thus the strength of FH
binding to C3b/C3u and to heparin are similar, indicating that FH
serves as a scavenger of C3b deposited on host cell surfaces in order
to regulate C3b.
The next strongest interactions of FH are with ligands such as
C3d (KD of 3–8 M and CRP (KD of 4 M)  (Okemefuna et al. 2009b,
2010b) (Table 1). These weaker afﬁnities concur with the view
that, during excess inﬂammation (acute phase response) with large
amounts of C3b present, abundant amounts of C3d and CRP are
available. When these are bound to host cell surfaces (Fig. 11), they
will provide additional FH binding sites to reinforce host cell protec-
tion. Zinc needs to be in large excess in order to inhibit the FH–C3b
interaction, given that the FH–zinc KD is larger still at about 10 M,
however the amount of bioavailable zinc present in drusen (Lengyel
et al. 2007) appears sufﬁcient to enable this. The future availability
of more KD values will complete this picture of the FH afﬁnities for
its ligands, including a consideration for the effect of other plasma
proteins on the FH–ligand interactions.
Many of the discrepancies in the recent FH literature in rela-
tion to KD values result because (i) it is not always appreciated
that FH and its C3 and CRP ligands each self-associate (Fig. 4), and
that this self-association can be turned to advantage in charac-
terising FH–ligand interactions; (ii) FH interacts weakly with its
ligands (Table 1), and consequently the physiologically importantface plasmon resonance studies to determine KD values do not give
consistent values between different laboratories. If surface plas-
mon  resonance experiments report M KD values within the range
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Fig. 13. A schematic model for the FH–zinc interaction. A mechanistic model for the zinc-induced aggregation of FH is based on two possible weak zinc binding sites at the
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f a single log unit, the functional conclusions are little affected.
rom these experiments, if the protein and ligand concentrations
re 5 M while the KD value is 20 M,  only 17% of the complex will
e formed. If the protein and ligand concentrations are 5 M and
he KD value is 100-fold stronger at 0.2 M,  only 82% of the complex
ill be formed. The frequent presumption of full 100% complex for-
ation for the FH interactions with C3b, anionic glycosaminoglycan
nalogues and other ligands in physiological conditions is wrong,
ven though (for example) it is possible to crystallise FH–C3b com-
lexes. It follows that bacterial evasion strategies that involve the
imicry of FH only require KD values that are below the M val-
es for the FH–C3b interaction. It is clear that the most important
omplement protein–protein interactions with FH correspond to
 balance between unbound and bound species. Incomplete com-
lex formation explains the “double-edged sword” of complement
ctivation and regulation (Zipfel and Skerka 2009; Ricklin et al.
010).
Four different types of FH oligomers have been observed to
ate:
(i) The oligomers formed through FH self-association are
attributed to interactions between pairs of SCR-6/8 and pairs of
SCR-16/20 domains. Additional interaction sites are not ruled
out. Through self-association, daisy-chains of structurally well-
deﬁned FH oligomers are formed that range between dimers
and monomers. FH oligomers amount to about 5–14% of the
total FH present. Oligomers are formed in a wide range of buffer
conditions, implying that FH oligomers exist in not only the
test-tube but also in the environment of 70 mg/ml of plasma
proteins.
(ii) C3d promotes FH oligomer formation. Using SCR-16/20, as
much as 24% of C3d–FH oligomers can be formed in addition to
the 5–14% of FH oligomers. The recent crystal structure of SCR-
19/20 with two C3d molecules (Kajander et al. 2011) suggests
that this results because of two C3d binding sites in SCR-19/20.
iii) Heparin induces the formation of well-deﬁned ring-like
oligomers of FH and heparin in alternation with each other,
provided that heparin is dp18 or larger in size. These larger
heparin fragments are big enough to crosslink the two heparin
sites at SCR-7 and SCR-20 between different FH molecules.ed by sequential zinc sites (Nan et al. 2011). An octamer of FH molecules is shown
 domains in FH explains how FH aggregates and precipitates in the presence of a
(iv) Zinc induces heavy aggregate formation in FH by cross-linking
pairs of half-zinc binding sites within the SCR-6/8 region of
FH. Unlike the FH–FH, FH–C3d and FH–heparin oligomers, the
FH–zinc aggregates do not possess well-deﬁned structures. Ill-
deﬁned FH–copper aggregates are also formed, and these are
distinct from those formed by FH–zinc (Nan et al. 2008b).
FH oligomer formation is suppressed by two of the ﬁve FH
ligands.
(i) The small heparin fragments (dp6, dp12) lead to small
decreases in the formation of FH oligomers without cross-
linking FH to form large oligomers. This shows that the heparin
binding sites compete with those for FH oligomer formation,
and was useful in showing that FH and heparin interacted with
each other (Khan 2011).
(ii) The addition of CRP to FH suppressed both the formation of
FH oligomers and CRP decamers (Fig. 9). This FH–CRP ultra-
centrifugation experiment was crucial for establishing that this
interaction existed, provided of course that the other com-
plications involving protein concentrations, buffers, and CRP
denaturation had been taken into account.
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